Glycerol phenylbutyrate, sold under the brand name Ravicti, is a nitrogen-binding agent medication used in the treatment of certain inborn urea cycle disorders.

The medication works by preventing the harmful buildup of ammonia in the body.

[5] It was developed by Hyperion Therapeutics based on the existing medication sodium phenylbutyrate, and received approval in February 2013.

[6] Glycerol phenylbutyrate is indicated for chronic management of people with urea cycle disorders who cannot be managed by dietary protein restriction and/or amino acid supplementation alone.

This drug article relating to the gastrointestinal system is a stub.